Background: Deconvoluting protein kinase signaling pathways using conventional genetic and biochemical approaches has been difficult because of the overwhelming number of closely related kinases. If cell-permeable inhibitors of individual kinases could be designed, the role of each kinase could be systematically assessed.
Background
Protein phosphorylation is a central mediator of many different cell-signaling events. The dissection of kinase signaling pathways is a challenge to existing biochemical and genetic methods for several reasons. The pathways are highly interconnected, and biochemical studies of individual kinases have revealed remarkable functional similarities between kinases [1] . Also, many kinase gene knockouts have shown surprisingly mild phenotypes, either because kinases recognize substrates redundantly or because of compensation by other kinases during development [2] [3] [4] . Cell-permeable inhibitors that are highly specific for one protein kinase would provide several key advantages over the gene 'knockout' approach to enzyme inactivation. Inhibitor treatment allows the cell no time to compensate adaptively for the missing activity of the target kinase. In addition, small molecules can be administered to a cell in varying concentrations, allowing observation of the effects of partial as well as total inhibition of the target kinase. Finally, inhibition of kinase activity at the catalytic active site in the Src-homology 1 (SH1) domain would presumably not disrupt important cellular localization and protein-protein binding interactions that are generally mediated through other domains [1] .
Despite their value in signal-transduction research, highly selective kinase inhibitors have proven very difficult to obtain. This is presumably because of the enormous size of the kinase superfamily and the highly conserved nature of kinase active sites, which make the design of an inhibitor that targets a given kinase an enormously challenging combinatorial problem [1, [5] [6] [7] . The development of kinase-specific inhibitors has been a major focus of antitumor drug discovery research because of the ubiquitous connection between oncogenic transformation and constitutively active protein kinases [8] [9] [10] . Recently, significant progress has been made in the synthesis and identification of molecules that can discriminate between different receptor tyrosine kinases. Molecules that are highly selective for epidermal growth factor receptor (EGF-R) [11, 12] , platelet-derived growth factor receptor (PDGF-R) [13] and fibroblast growth factor receptor (FGF-R) [14, 15] tyrosine kinases have been identified. Importantly, crystal structures of inhibitors bound to kinases [15] and modeling studies [12, 16] are facilitating the structure-based design of highly selective molecules. Despite these efforts, few inhibitors that are entirely specific for a single cytoplasmic protein kinase have been identified [17] , and no general methods for specifically targeting a given kinase have been described.
We have devised a combined chemical and genetic strategy that allows for the generation of 'chemical-sensitive' mutant kinases each of which is uniquely inhibited by a rationally designed small-molecule inhibitor. Our approach involves engineering into the active site of the kinase of interest a unique 'pocket' resulting from the introduction of a functionally silent mutation. A specific inhibitor of the engineered kinase is then synthesized by derivatizing a known kinase inhibitor with a bulky chemical group designed to fit the novel active-site pocket. The bulky group prevents the compound from inhibiting wildtype kinases, which do not have the pocket. Successful complementary design therefore results in interactions between only the engineered kinase and the inhibitor. Transfection of cells with the gene encoding the engineered kinase generates cells in which only this one kinase can be blocked by the designed inhibitor ( Figure 1 ). Importantly, because the mutant kinase has the same biological function as the wild-type kinase, an inhibitor of the mutant will affect cell signaling in the same manner as would a selective inhibitor of the endogenous kinase. The ability to observe the phenotype of cells after selective inhibition of a protein kinase provides a rapid method for determining the unique roles of individual kinases in signal-transduction cascades.
We have targeted the Src family of protein tyrosine kinases for specific inhibitor design because of their ubiquitous functional importance in cells [3, 18] . Despite intense investigation, the roles of individual Src family members have been difficult to assess because many of them co-localize in cells and many have similar sequences. Although some potent inhibitors of Src family kinases are known [19, 20] , no molecules have been identified that can effectively discriminate (≥ 20-fold selectivity for one Src family member) between these closely related enzymes [10] .
Two Src kinases, v-Src and Fyn, were chosen as the primary targets of our mutant kinase-inhibitor pair design. Src kinase has emerged as a leading drug target because of its implication in the oncogenesis of breast, lung and colon cancers [10] . Although v-Src is the prototype for oncogenic tyrosine kinases, no small-molecule inhibitors that are highly selective for this kinase have been discovered [10] . Fyn is a Src family tyrosine kinase that is important in lymphocyte activation mediated by the T-cell receptor [3, 21] . Src and Fyn share a similar domain structure and have approximately 85% amino-acid identity in their catalytic domains [22] . The close structural relationship of the Src family members provides the ideal test of our ability to engineer enzyme-inhibitor specificity that can distinguish between highly homologous kinases. If one can discriminate between these closely related Src family members using a cell-permeable inhibitor, it is likely that specificity for members of other protein-kinase families can also be achieved using a similar approach.
Results and discussion

Enzyme engineering
From our previous efforts to engineer kinases with novel ATP specificity [23, 24] , we identified a functionally conserved residue (Ile 338) in the ATP-binding pocket of vSrc that could be mutated to glycine without altering the phosphoacceptor specificity or biological function of the kinase. The mutation (I338G) causes only a modest drop in the k cat of v-Src, a modest increase in the K m for ATP [24] and no quantitative change in the level of fibroblast transformation compared to the non-engineered ('wildtype') protein (K.S., unpublished observations). Crystal structures of ATP-bound protein kinases have in all cases revealed close contact and interaction between the residue corresponding to 338 in Src and ATP [25] [26] [27] [28] . Analysis of protein kinase sequence alignments confirms that residue 338 contains a bulky side chain (usually threonine, isoleucine, leucine, methionine or phenylalanine) in all known eukaryotic protein kinases [29] . Thus, the mutation to glycine at residue 338 should create a novel pocket that is not present in any wild-type kinase. Because of the expanded ATP-binding site, the glycine mutant kinases should bind bulky inhibitors that could not bind wild-type kinases. Using standard methods, we cloned, expressed and purified the glutathione-S-transferase (GST) fusion protein of the wild-type and I338G v-Src catalytic domains as described [23, 24] . Wild-type Fyn, T339G Fyn and the wild-type Abl tyrosine kinase were also expressed and purified as GST fusion proteins.
Inhibitor design and synthesis
To test our basic design strategy, we screened the wildtype and I338G v-Src SH1 domains against a previously synthesized panel of N-6-substituted adenosine molecules [23] for selective inhibition of I338G v-Src over wild-type v-Src. Because adenosine is only a moderate inhibitor of Src family tyrosine kinases, we did not expect to discover a potent inhibitor of the engineered kinase. As expected, all of the N-6 adenosine analogues inhibited I338G v-Src more potently than wild-type v-Src (data not shown). The most potent inhibitor found in this screen was N-6 cyclopentyloxyadenosine (1, Figure 2a ) with a 50% inhibitory concentration (IC 50 ) of 1 µM for I338G v-Src. Subsequent experiments to test for selectivity demonstrated that N-6 cyclopentyloxyadenosine showed no detectable in vitro inhibition of wild-type v-Src or Fyn at concentrations up to 400 µM. This first screen encouraged us to pursue the strategy of developing novel inhibitors of I338G v-Src because our design had allowed us readily to overcome the selectivity barriers that are major problems in conventional inhibitor design.
As inhibitors, adenosine analogues are not ideal because adenosine performs many cellular functions and binds a large number of cellular proteins. N-6 adenosine analogues have been shown to act as adenosine-receptor agonists and antagonists [30] , and N-6 adenosine analogues might conceivably act as substrates for nucleoside kinases. For these reasons, we turned to a class of known tyrosine-kinase inhibitors that are not direct analogues of biologically known molecules. Our design strategy called for a core structure that exhibits potent inhibition of multiple wildtype kinases and is easily synthesized. Also, the binding orientation of the molecule in the enzyme active site must be known or readily predictable. In addition, the molecule must bind in a manner in which the site pointing toward Ile338 can be easily modified. As our core inhibitor structure we chose 4-amino-1-tert-butyl-3-phenylpyrazolo [3,4-d] pyrimidine (2, Figure 2b ). This molecule is a derivative of 4-amino-1-tert-butyl-3-(p-methylphenyl)pyrazolo [3,4-d] pyrimidine (PP1) that was reported to be a potent Src family kinase inhibitor by Hanke and co-workers [19] . On the basis of the co-crystal structure of the Src family kinase Hck bound to the general kinase inhibitor quercetin The specificity problems associated with using small-molecule proteinkinase inhibitors to deconvolute cell signaling. Kinase catalytic domains (red ovals) are highly conserved. Thus, (a) the majority of potent inhibitors block the activity of closely related kinases and broadly down-regulate pathways mediated by kinase activity. (b) The selective protein kinase inhibition approach described here. A space-creating mutation is introduced into the ATP-binding site of the kinase of choice (Src). This mutation creates an active-site pocket in Src that can be uniquely recognized by the rationally designed small-molecule inhibitor. The inhibitor contains a bulky chemical group that makes it unable to bind wild-type protein kinases. Design of the complementary kinase-inhibitor pair allows for highly selective inhibition of the target kinase in the context of a whole cell. S indicates serine and Y indicates tyrosine.
(5, Figure 3 ) [25, 31] , we postulated that 2 binds to Src family kinases in a conformation similar to that of ATP. The predicted binding orientation of 2 in Hck is shown in an overlay with the known Hck co-crystal structures of AMPPNP (6) and quercetin ( Figure 3b ) [25] . In this conformation, the easily derivatizable N-4 position of 2 corresponds to the N-6 of ATP (close contact with residue 338, Figure 3c ) and the tert-butyl moiety roughly corresponds to the ribose ring of ATP. We further hypothesized that, in this orientation, the C-3 phenyl ring of 2 could bind in a pocket that surrounds the N-7 of ATP as seen in the Hck-quercetin co-crystal structure [25] . This analysis led us to synthesize a small panel of N-4 derivatized analogues of 2 [32, 33] (Figure 2 ).
Identification of a uniquely selective inhibitor
The panel of pyrazolo [3,4-d] pyrimidines was screened against wild-type and I338G v-Src kinases ( Table 1 ). All of the analogues were better inhibitors of the engineered vSrc than of wild-type v-Src, confirming our prediction of the binding orientation of 2 in the kinase active site. Any derivatization of 2 at the N-4 position destroyed the inhibitory activity against wild-type v-Src (no detectable inhibition at the limit of solubility, 300 µM). of wild-type v-Src. The size of the derivatization needed to achieve sub-micromolar potency for the I338G v-Src active site was rather unexpected. We removed only four carbon atoms from the ATP-binding site of the protein and added 11 carbon atoms to the parent molecule. This discrepancy may be due to an imperfection in our binding prediction. Alternatively, the isoleucine to glycine mutation may confer greater flexibility on the enzyme active site, allowing the mutant kinase to accept a larger inhibitor analogue than predicted [24] . To confirm that 3g does inhibit I338G v-Src at the ATP-binding site, we investigated the kinetics of inhibition at various ATP concentrations. LineweaverBurk analysis confirmed that 3g does inhibit I338G v-Src competitively with respect to ATP with an inhibitory constant (K i ) of 380 nM (data not shown).
The 10 inhibitor analogues were then screened against wild-type Fyn to investigate their potential to cross-react with this kinase. Wild-type Fyn was chosen as the 'worst case' control of wild-type kinases because both 2 and its parent molecule, PP1, are highly potent (low nanomolar) inhibitors of Fyn [19] . Many of the inhibitor analogues were not highly selective for the target kinase ( Table 1 ).
The N-acyl analogues with saturated ring systems (3a-3c) effectively inhibited wild-type Fyn. The N-methylene compounds (4b-4e) were sufficiently inactive against wildtype Fyn but showed only poor to moderate inhibition of I338G v-Src. Importantly, 3g, the most potent inhibitor of the mutant v-Src, inhibited wild-type Fyn very weakly (IC 50 = 300 µM). Thus, 3g inhibits the engineered v-Src over 700 times more effectively than it inhibits wild-type Fyn, which is likely to be the wild-type cellular kinase that is the most capable of binding the molecule. We also tested whether other non-Src family kinases were fortuitously inhibited by 3g in vitro. Inhibition of the serine/threonine kinases protein kinase C δ (PKCδ) and protein kinase A was not detected at inhibitor concentrations up to 300 µM. Likewise, 3g exhibited only weak inhibition (IC 50 > 300 µM) of Abl. The 3g compound therefore satisfied all of our initial design requirements for potent selective inhibition of one engineered kinase.
Selectivity in whole cells
To demonstrate further that 3g does not inhibit wild-type tyrosine kinases, we investigated the effects of 3g treatment on the phosphorylation cascade triggered by activation of the B-cell receptor. Src family (Fyn, Lyn, Lck, Blk) and non-Src family (Btk, Syk) tyrosine kinases are known to be activated upon cross-linking of the B-cell receptor [34] . Because of the amplifying nature of the B-cell receptor signaling cascade, inhibition of any of the downstream kinases would dramatically alter the distribution and intensity of post-activation cellular phosphotyrosine [35] . Because 3g was designed to be sterically incompatible with the active sites of wild-type kinases, it should not disrupt tyrosine-phosphorylation-dependent signaling in wild-type B cells. Figure 4 shows that treatment of murine B cells that had had their antigen receptor cross-linked with 100 µM 3g had no effect on the phosphotyrosine pattern of B-cell stimulation (compare lane 3 to lane 2).
The signal intensities of all the major bands were unchanged and only slight depletion of some minor bands is detectable, confirming that 3g does not appreciably inhibit the panel of tyrosine kinases that are activated by cross-linking the B-cell receptor. Treatment of B cells with 100 µM 2, however, caused a significant reduction in tyrosine phosphorylation (Figure 4 , lane 4) that is consistent with the ability of 2 to potently inhibit wild-type Src family kinases [19] .
Selective inhibition of I338G v-Src in NIH3T3 cells
In order to use our selective inhibitor to study a Src-mediated pathway, we delivered genes encoding either wildtype or I338G v-Src into NIH3T3 fibroblasts via retrovirus infection [36] . These cells acquired a transformed phenotype that was dependent on v-Src expression. We sought to show that 3g could selectively inhibit the Src-dependent signal-transduction pathway of I338G v-Src transformed cells but not affect cells transformed with wild-type v-Src. Cells infected with wild-type v-Src showed no loss of tyrosine phosphorylation when treated with 100 µM 3g compared to control treatment with dimethyl sulfoxide (DMSO; Figure 5 ), demonstrating that 3g does not inhibit wild-type v-Src or any of the other tyrosine kinases that are activated by v-Src-mediated . It has been shown previously that treatment of v-Src-transformed cells with general tyrosine kinase inhibitors causes a reduction in the tyrosine phosphorylation of a 36 kDa protein [31] . It is thought that p36 is associated with a specific phosphotyrosine phosphatase, possibly explaining its rapid dephosphorylation in inhibitor-treated cells [37] . The IC 50 of 3g for the p36 phosphotyrosine signal in cells expressing I338G v-Src was ~50 µM, roughly 100 times the in vitro value (data not shown). This is presumably because the inhibitor must compete for the kinase active site with millimolar concentrations of ATP in the cellular environment [9] .
Selective inhibition of I338G v-Src reverses transformed cell morphology
The activity of v-Src is required for the transformation of mammalian cells by the Rous sarcoma virus [38, 39] .
Treatment of NIH3T3 cells expressing I338G v-Src with 100 µM 3g caused dramatic changes in cell morphology that are consistent with the reversal of transformation ( Figure 6 ); the cells appeared flat and did not exhibit the growth characteristics of transformed cells (that is, the ability to grow on top of one another). Under identical conditions, cells infected with wild-type v-Src demonstrated the typical rounded morphology and overlapping growth patterns of transformed cells.
To demonstrate further the selective reversal of cell morphology, we used fluorescence microscopy to view 3g-treated cells after staining the cellular polymerized actin with fluorescein isothiocyanate-phalloidin ( Figure 6 ). Non-transformed NIH3T3 cells have long actin fibers that form across the cells [40] . Cells transformed with v-Src (both wild-type and I338G forms) appeared rounded with no discernible pattern of actin fibers. In agreement with the light microscopy data, inhibitor-treated cells expressing wild-type v-Src appeared indistinguishable from and showed peripheral actin staining that was not present in the non-transformed NIH3T3 cells. These data show that 3g can induce morphological changes in cells that are engineered to contain a single amino-acid change in the kinase of interest. This is the first demonstration that a small-molecule inhibitor selective for a tyrosine-kinase oncogene product can revert the morphological changes associated with cellular transformation. Previous examples of morphological reversion of transformation by herbimycin A (and other benzoquinone ansamycins) have recently been shown to operate via a mechanism that is not related to kinase inhibition and consists of targeting of the oncogenic tyrosine kinase to the proteasome by use of the heat-shock protein Hsp90 [41] [42] [43] [44] .
Generalization to other kinases
The advantage of using mutagenesis to provide a unique molecular difference between the enzyme of interest and all other enzymes is that the approach should be extendible across the kinase superfamily, because the kinase fold is conserved. Almost all known protein kinases contain a bulky side chain at the position corresponding to residue 338 of v-Src. A space-creating mutation at this position should therefore render any kinase susceptible to selective inhibition. To test this, we measured the inhibition of T339G mutant Fyn by the analogues ( Table 1 ). The structure-activity relationships of the analogues for I338G v-Src and T339G Fyn were found to be strikingly similar. The 3g compound was the most potent inhibitor analogue against T339G Fyn, as it was for I338G v-Src, exhibiting an IC 50 of 830 nM. This corresponds to greater than 300-fold selectivity for T339G Fyn over wild-type Fyn. The implication from these data is that multiple tyrosine kinases can be systematically engineered to accept one inhibitor analogue preferentially without the need to screen large libraries of putative inhibitors.
Conclusions
In this report, we describe a novel approach to selective protein kinase inhibition through the complementary engineering of kinases sensitive to specific chemicals and rationally designed inhibitors. We demonstrate that high selectivity for the target kinase can be achieved in whole cells, and that active-site inhibition of an oncogenic tyrosine kinase can be sufficient for the disruption of a transformed cell morphology. Because the approach is easily generalized, it should have far-reaching applications in deconvoluting signal-transduction pathways, as well as in the validation of kinases as targets for drug design. The pace of effective drug discovery is limited by the identification and validation of important drug targets. This is not a trivial problem in a milieu of homologous proteins that may potentially number 2000. The use of chemical-sensitive mutants of protein kinases expands the ability to probe the cellular and physiological effects of pharmacological kinase inhibition. As transfected cell lines and even 'knock-in' mice expressing a mutant protein of interest can now be generated rapidly, our approach should greatly expedite the process of testing the effects of selective inhibition of a given kinase in a whole-cell or animal model. As more inhibitor-bound protein kinase crystal structures become available, our strategy will allow for the systematic investigation of the effects of time-dependent and Research Paper Allele-specific inhibitors of Src kinases Bishop et al. 263
Figure 6
Fibroblasts transformed with I338G v-Src acquire a flattened morphology and regain actin stress fibers when they are incubated with 3g. (a,b) Non-transformed, (c,d,g,h) wild-type v-Src-transformed, and (e,f,i,j) I338G v-Src-transformed NIH3T3 fibroblasts were treated with either 1.1% DMSO (a-c,e,g,i) or 100 µM 3g in 1.1% DMSO (d,f,h,j). After 48 h, cells were photographed (a,c-f), stained with FITC-phalloidin, and visualized by fluorescence microscopy (b,g-j). 
Materials and methods
Chemical synthesis
All starting materials and synthetic reagents were purchased from Aldrich unless otherwise noted. All compounds were characterized by 1 H NMR and high resolution mass spectrometry. 4-amino-1-tert-butyl-3-phenylpyrazolo [3,4-d] pyrimidine (2) was synthesized according to Hanefeld et al. [32] .
General procedure for N-4 acylation of 2 (3a-3g):
To a solution of 2 (~100 mg) dissolved in 2 ml pyridine was added 10 equivalents of the desired acyl chloride at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 12 h. The reaction was quenched by the addition of 25 ml water. [3,4-d] [3,4-d] [3,4-d] General procedure for the reduction of N-4 acyl compounds to N-4 methylene compounds (4b, 4d, 4e): A round bottom flask was charged with ~30 mg LiAlH 4 . The flask was equipped with a pressure equalizing dropping funnel and flushed with dry argon. The LiAlH 4 was suspended in 3 ml THF over an ice bath. Approximately 100 mg of the corresponding N-4 acyl 2 analogue was dissolved in 5 ml THF and added dropwise to the suspension of LiAlH 4 . The reaction mixture was stirred for 30 min on the ice bath and subsequently heated to reflux for 30 min. The reaction was quenched by the sequential, dropwise additions of 1 ml EtOAc, 1 ml water, and 1 ml 6 N NaOH. After stirring for 5 min, the reaction mixture was filtered through a celite pad, diluted with water and extracted with Et 2 O. The Et 2 O extracts were combined, dried over MgSO 4 , and evaporated. The residue was purified by flash chromatography on 10 g of silica gel by elution with 4:1 hexanes : EtOAc. [3,4- [3,4- 
4-benzamido-1-tert-butyl-3-phenylpyrazolo
4-(p-methyl)benzamido-1-tert-butyl-3-phenylpyrazolo
4-(p-tert-butyl)benzamido-1-tert-butyl-3-phenylpyrazolo
4-cyclopentylmethylamino-1-tert-butyl-3-phenylpyrazolo
4-2′-furylmethylamino-1-tert-butyl-3-phenylpyrazolo
Protein expression and purification
Site-directed mutagenesis and cloning of the genes for the glutathione-S-transferase fusion proteins of wild-type v-Src SH1 domain, I338G vSrc SH1, wild-type Fyn, T339G Fyn, and wild-type Abl into the pGEX-KT plasmid was carried out as described [23] . These kinases were expressed in DH5α Escherichia coli and purified on immobilized glutathione beads (Sigma). PKA was purchased (Pierce) and used without further purification. PKCδ was expressed as the 6-His construct using the Bac-to-Bac expression system (pFastBac B vector). PKCδ was purified using a QIAexpress Ni-NTA agarose column.
In vitro kinase inhibition assay
IC 50 values for putative kinase inhibitors were determined by measuring the counts per minute (cpm) of 32 P transferred to an optimized peptide substrate for Src family kinases (IYGEFKKK, in single-letter amino-acid code). Various concentrations of inhibitor were incubated with 50 mM Tris (pH 8.0), 10 mM MgCl 2 , 1.6 mM glutathione, 1 mg/ml BSA, 133 µM IYGEFKKK, 3.3% DMSO, 0.05 µM kinase and 11 nM (2 µCi) [γ-32 P]ATP (6000 Ci/mmol, NEN) in a total volume of 30 µl for 30 min. Reaction mixtures (25 µl) were spotted onto a phosphocellulose disk, immersed in 10% HOAc, and washed with 0.5% H 3 PO 4 . The transfer of 32 P was measured by standard scintillation counting. The IC 50 was defined to be the concentration of inhibitor at which the cpm was 50% of the control disk. When the IC 50 fell between two measured concentrations it was calculated based on the assumption of an inversely proportional relationship between inhibitor concentration and cpm between the two data points. Because the solubility limit of the inhibitor analogues in aqueous solutions is ~300 µM, IC 50 values of ≥250 µM are approximate as full titrations to the upper limit of inhibition could not be tested. IC 50 values for non-Src family kinases were measured equivalently with the following exceptions. Kemtide (Pierce, 133 µg/ml) was used as the substrate for PKA. An optimized Abl substrate (EAIYAAP-FAKKK, 133 µg/ml) was used for Abl assays. PKCδ assays were performed in the presence of 17 ng/ml diacyl glycerol (Sigma) and 17 ng/ml phosphatidyl serine (Sigma) with 170 ng/ml histone (Sigma) as the kinase substrate.
Murine B-cell assay
Splenic lymphocytes were isolated from 6-20 week old Balb/c or C57/B6 mice. The cells were washed out of the spleen into RPMI media containing 1 µg/ml DNase I and the red-blood cells were lysed in 17 mM Tris-ammonium chloride, pH 7.2. Approximately 4 × 10 6 cells were incubated at 37°C for 30 min with 100 µM of 3g or 2 in 1.1% DMSO. B-cell stimulation was initiated by the addition of 2 µg of goat anti-mouse IgM (Jackson Immuno Research, 115-005-075) and subsequent incubation for 5 min at 37°C. The cells were isolated by centrifugation (13,000 rpm, 2 min) and lysed (lysis buffer: 1% Triton X-100, 50 mM Tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 100 µM PMSF, 2 mM sodium orthovanadate, 10 µg/ml leupeptin, 10 µg/ml apoprotin). The cellular debris was then pelleted at 13,000 rpm for 15 min. Cellular proteins were separated by 10% polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane by western blotting. Phosphotyrosine-containing proteins were visualized by immunoblotting with anti-phosphotyrosine antibody (Upstate Biotechnology).
Retroviral infection of NIH3T3 fibroblasts
Genes encoding wild-type and I338G v-Src were transfected into a packaging cell line and NIH3T3 fibroblasts were retrovirally infected using the pBabe retroviral vector and a puromycin (2.5 µg/ml) selectable marker as described [36] (K.S., Y.L., K.M.S., unpublished observations). Cells transformed with wild-type and I338G v-Src were cultured in DMEM/10% BCS containing 2.5 µg/ml puromycin.
Inhibition of v-Src in NIH3T3 fibroblasts
Non-transformed NIH3T3 cells and NIH3T3 cells transformed with wild-type v-Src or I338G v-Src were incubated at 37°C with 1.1% DMSO or 100 µM 3g in 1.1% DMSO. After 12 h, the cells were washed with PBS and lysed (lysis buffer: 1% Triton X-100, 50 mM Tris pH 7.4, 2 mM EDTA, 150 mM NaCl, 100 µM phenylmethylsulphonyl fluoride, 2 mM sodium orthovanadate, 10 µg/ml leupeptin, 10 µg/ml apoprotin). The lysate was clarified by centrifugation at 13,000 rpm for 15 min. Lysate protein concentrations were normalized and equal volumes of the lysate were resolved by electrophoresis and analyzed for phosphotyrosine content as described above.
Microscopy
NIH3T3 fibroblasts that were non-transformed or transformed with wild-type or I338G were grown in DMEM/10% BCS on slides treated for tissue culture. Cells expressing v-Src were treated with either 1.1% DMSO or 100 µM 3g in 1.1% DMSO. After 48 h cells were photographed at 400× magnification through a Nikon TMS light microscope. Immediately following light microscopy, the cells were fixed for 20 min in 3.7% formaldehyde/PBS and permeabilized for 60 sec in 0.2% Triton X-100/PBS. Permeabilized cells were incubated with 200 ng/ml FITC-phalloidin/PBS for 20 min. Slides were rinsed with PBS and polymerized actin was visualized by fluorescence microscopy at 600× magnification on a Zeiss fluorescence microscope.
